Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
84M shares
52-week range
$5.95 – $62.75
25% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $5.0K | $0 | $0 | $0 | $2.6M |
| Gross profit | $0 | −$5.0K | $0 | $0 | $0 | −$2.6M |
| Gross margin | — | — | — | — | — | — |
| R&D | $0 | $35.5M | $42.0M | $31.8M | $112.8M | $202.9M |
| Operating income | −$105.8K | −$53.6M | −$65.1M | −$54.1M | −$143.1M | −$244.8M |
| EBITDA | −$90.8K | −$53.6M | −$64.3M | −$43.6M | −$119.6M | −$219.8M |
| Net income | −$90.8K | −$53.6M | −$50.0M | −$36.0M | −$118.9M | −$227.3M |
| Net margin | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -1.45 | -2.20 | -0.73 | -1.89 | -3.53 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-3.83 | $-4.29–$-3.36 | 8 |
| 2027 | $23M | $-3.64 | $-4.34–$-2.95 | 8 |
| 2028 | $136M | $-2.90 | $-4.29–$-1.38 | 7 |
| 2029 | $443M | $-0.83 | $-0.95–$-0.71 | 2 |
Forward consensus · source: Financial Modeling Prep
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
www.moonlaketx.comNo one on the platform currently holds MLTX.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 276,772 | $5.2M |
No one on the platform has traded MLTX yet.
| $5.7B |
| — |
| MBXMBX Biosciences, Inc. Common Stock | $53.85 | +2.94% | $1.8B | — |
| MGTXMeiraGTx Holdings plc | $12.54 | +3.55% | $1.2B | — |
Source: Financial Modeling Prep · peers by sector/industry
$MLTX The ultimate truth: No buyer wants a stock to stay pinned forever.Hedge funds and institutional buyers do not make money by holding a stock flat; they make money on the explosive upward move. They are intentionally keeping it pinned right now to build the biggest position possible. The moment a massive catalyst hits, the entire landscape changes.
View on StockTwits ↗$MLTX One day we will wake up and there will be BIG news.
View on StockTwits ↗$MLTX BVF was diluted like the rest of us. They went from 22% to 19.7%. Let's get this sucker sold! https://www.sec.gov/Archives/edgar/data/1821586/000092189526001697/xslSCHEDULE_13D_X02/primary_doc.xml
View on StockTwits ↗$MLTX I see they just updated ownership as per new OS
View on StockTwits ↗$MLTX when folks who call themselves "tendies" show up less then two weeks ago and immediately start lecturing those "new here," my red flag goes right up. Blocked him today.
View on StockTwits ↗$MLTX It's trading right now like a pinned dividend stock--everyone is just waiting at this point.
View on StockTwits ↗$MLTX the price action has been incredibly fascinating. Pin pointed to 20$. Insane. it damn it kinda is beautiful to watch.
View on StockTwits ↗$MLTX The guy calling the shots on a Buyout is Mark Lampert. Bihua Chen and David Kroin will have input too. The same 3 funds which all moved money around for this $200 million equity raise. Mark, David & Bihua are really the head of MLTX. Jorge is competent in a lot of areas, but naive in others. This is his 1st Rodeo. He's made mistakes but when you have the experience of Mark Lampert in the background directly involved, major fuck-ups won't happen. Mark's been around as long as I have and he's as research oriented as I am. He has his finger on the switch & no one makes any major move at MLTX without his okay. He is very active in coaching management. VERY ACTIVE. Jorge is learning from a true veteran & has made clear errors but nothing a great drug can't hide. Make no mistake, Mark Lampert is here to maximize Buyout $ and nothing else. Smile guys, there's a huge buyout guarantee here. You've got a guy whose sole purpose in life is squeezing BP for every $ can get.
View on StockTwits ↗$MLTX Still adding when able. No doubt in my mind this is gonna do mult x over time.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.